Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B78e2cb4bef230852d92c07971b32fef5> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B78e2cb4bef230852d92c07971b32fef5 NCIT_P378 "NCI" @default.
- B78e2cb4bef230852d92c07971b32fef5 type Axiom @default.
- B78e2cb4bef230852d92c07971b32fef5 annotatedProperty IAO_0000115 @default.
- B78e2cb4bef230852d92c07971b32fef5 annotatedSource NCIT_C113432 @default.
- B78e2cb4bef230852d92c07971b32fef5 annotatedTarget "A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines." @default.